Charles Steven Myers

US Patent:

51589400, Oct 27, 1992

Filed:

Feb 14, 1990

Appl. No.:

7/479817

Inventors:

Renato V. LaRocca - Sterling VA
Cy A. Stein - Gaithersburg MD
Michael R. Cooper - Gaithersburg MD
Charles E. Myers - Rockville MD

Assignee:

The United States Government as represented by the Secretary, DHHS - Washington DC

International Classification:

A61K 31715

US Classification:

514 54

Abstract:

Polysulfonated compounds such as suramin are used to treat immunoregulatory isorders. Particular use in the treatment of rheumatologic diseases such as rheumatoid arthritis is shown.

US Patent:

60403349, Mar 21, 2000

Filed:

Oct 20, 1994

Appl. No.:

8/330865

Inventors:

Charles Myers - Rockville MD
Jane Trepel - Bethesda MD
Won Ki Kang - Rockville MD
Luke Whitesell - Bethesda MD
Len Neckers - Bethesda MD

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

A61K 3135

US Classification:

514460

Abstract:

Methods of treating various cancers, such as prostatic adenocarcinoma, with inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG Co-A), such as lovastatin, are provided. Dosing ranges, schedules and toxicities are included.

US Patent:

56415001, Jun 24, 1997

Filed:

May 15, 1995

Appl. No.:

8/446954

Inventors:

Jane B. Trepel - Bethesda MD
Farzaneh Pirnia - Potomac MD
Charles E. Myers - Rockville MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 3170
A61K 908

US Classification:

424422

Abstract:

The instant invention is directed to the use of a pharmaceutical composition containing an effective amount of adenosine or an adenosine analog or derivative as an agent useful in the treatment of hormone-independent cancers, such as prostate cancer. The invention is also directed to diagnostic uses of these compounds to determine effective treatment regimes for specific tumors, a process for screening for new, therapeutically useful analogs of these compounds, and the use of these compounds in facilitating the extraction of intracellular components.

US Patent:

43316484, May 25, 1982

Filed:

Sep 23, 1980

Appl. No.:

6/190064

Inventors:

Charles E. Myers - Rockville MD
James H. Doroshow - Upland CA
Gershon Y. Locker - Chicago IL

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

A61K 3170
A61K 3171

US Classification:

424 10

Abstract:

The cardiac damage, occurring after treatment with an anthracycline, such as adriamycin, is prevented when N-acetyl-cysteine is orally administered about one hour prior to the treatment with the anthracycline.

US Patent:

49862561, Jan 22, 1991

Filed:

Feb 28, 1985

Appl. No.:

6/706622

Inventors:

Jack S. Cohen - Bethesda MD
Chi-Wan Chen - Silver Spring MD
Charles E. Myers - Rockville MD
Miriam Sohn - Washington DC

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61B 1752

US Classification:

1286534

Abstract:

Water-soluble paramagnetic metalloporphyrins are used as contrast enhancing agents for magnetic resonance imaging. These agents exhibit excellent localization, non-toxicity and suprisingly high contrast enhancement in magnetic resonance imaging applications.

US Patent:

56021844, Feb 11, 1997

Filed:

Mar 3, 1993

Appl. No.:

8/025471

Inventors:

Charles E. Myers - Rockville MD
Jane Trepel - Bethesda MD
Edward Sausville - Silver Spring MD
Dvorit Samid - Rockville MD
Alexandra Miller - Hyattsville MD
Gregory Curt - Rockville MD

Assignee:

The United States of America as represented by Department of Health and
Human Services - Washington DC

International Classification:

H61K 31045

US Classification:

514739

Abstract:

The invention provides methods of treating cancer including administering an effective amount of selected terpenes to a mammal having the cancer when the cancer is prostate cancer, colon cancer, astrocytoma, or sarcoma. The terpene is selected from the group consisting of a cyclic monoterpene, a noncyclic monoterpene, a noncyclic sesquiterpene and a noncyclic diterpene. The invention also provides a method of sensitizing a cancer to radiation including administering an effective amount of a terpene to a mammal having the cancer wherein the terpene is selected from the group noted above. Additionally, the invention provides methods of inhibiting the growth of cancer cells including applying an effective amount of a selected terpene to the cancer cells which are cells of prostate cancer, colon cancer, osteosarcoma, or glioblastoma.

US Patent:

54158737, May 16, 1995

Filed:

Oct 4, 1993

Appl. No.:

8/131033

Inventors:

Jane B. Trepel - Bethesda MD
Farzaneh Pirnia - Potomac MD
Charles E. Myers - Rockville MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 3170
A61K 908

US Classification:

424422

Abstract:

The instant invention is directed to the use of a pharmaceutical composition containing an effective amount of adenosine or an adenosine analog or derivative as an agent useful in the treatment of hormone-independent cancers, such as prostate cancer. The invention is also directed to diagnostic uses of these compounds to determine effective treatment regimes for specific tumors, a process for screening for new, therapeutically useful analogs of these compounds, and the use of these compounds in facilitating the extraction of intracellular components.